The assumption that CT colonography is the logical choice for pairing with optical colonoscopy to stage colorectal cancer took a hit at the RSNA meeting today. A prospective study from Europe shows that whole-body FDG-PET/CT is significantly more accurate than CT colonography for staging colorectal tumors.
The assumption that CT colonography is the logical choice for pairing with optical colonoscopy to stage colorectal cancer took a hit at the RSNA meeting today. A prospective study from Europe shows that whole-body FDG-PET/CT is significantly more accurate than CT colonography for staging colorectal tumors.
The study of 52 patients performed by Dr. Peter Veit at the University of Essen in Germany found that whole-body FDG-PET/CT colonography was 74% sensitive for T-staging, compared with a sensitivity rate for CT colonography of 52%. The results were confirmed by histopathology specimens and clinical follow-up 310 days after the initial evaluation. Veit has since joined the nuclear medicine residency program at the University of Zurich in Switzerland.
FDG-PET/CT colonography contributed to alteration of the clinical management of four patients, Veit said. In one instance, PET/CT colonography uncovered a second liver metastasis that was not detected with CT colonography alone. That finding identified the need for a second surgical session to resect the second lesion.
No significant differences in metastasis or lymph node staging were observed.
PET/CT colonography takes about seven minutes longer than the conventional 30-second PET/CT whole-body protocol for colorectal cancer staging, Veit said. Additional time is needed for pharmacological bowel relaxation and rectal water filling.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.